Active not recruiting

A Study of LY3002813 in Participants With Early Symptomatic Alzheimer's Disease (TRAILBLAZER-ALZ)

I5T-MC-AACG - ClinicalTrials.gov - NCT03367403

The purpose of this study is to evaluate the safety, tolerability and efficacy of LY3002813 in early symptomatic Alzheimer's disease.
How long will I be in the trial?
Your participation could last up to 124 weeks and include up to 26 visits to the study center.
Email
Active not recruiting

A Study of LY3002813 in Participants With Early Symptomatic Alzheimer's Disease (TRAILBLAZER-ALZ)

I5T-MC-AACG - ClinicalTrials.gov - NCT03367403

The purpose of this study is to evaluate the safety, tolerability and efficacy of LY3002813 in early symptomatic Alzheimer's disease.
How long will I be in the trial?
Your participation could last up to 124 weeks and include up to 26 visits to the study center.
Email

Key Requirements

Age :

60-85

Sex:

All

Key Requirements

Use the following checklist to help determine if this trial may be a good fit for you. Place a checkmark next to each criteria that you successfully meet.

Age

60-85

Sex

All

Participants must

Participant must have gradual and progressive change in memory for at least 6 months

Participant must be able to have a positron emission tomography (PET) scan

Participant must be able to have an magnetic resonance imaging (MRI) scan - Participant receiving treatment with one of the symptomatic Alzheimer's drugs must be on a stable dose for at least 2 months

Participant must have a reliable study partner with whom they live or have regular contact (at least 10 hours of communication each week), and who can come to study visits

Participants must NOT

Trial Summary

Conditions the trial is for

Early Symptoms of Alzheimer's Disease

What the trial is testing?

LY3002813, Placebo (IV),

Could I receive a Placebo?

yes

Enrollment Goal

266

Trial Dates

December 2017 - November 2021

Trial Phase

2

Enter your postal code to find the nearest site

Key Requirements

Use the following checklist to help determine if this trial may be a good fit for you. Place a checkmark next to each criteria that you successfully meet.

Age

60-85

Sex

All

Participants must

Participant must have gradual and progressive change in memory for at least 6 months

Participant must be able to have a positron emission tomography (PET) scan

Participant must be able to have an magnetic resonance imaging (MRI) scan - Participant receiving treatment with one of the symptomatic Alzheimer's drugs must be on a stable dose for at least 2 months

Participant must have a reliable study partner with whom they live or have regular contact (at least 10 hours of communication each week), and who can come to study visits

Participants must NOT

Trial Summary

Conditions the trial is for

Early Symptoms of Alzheimer's Disease

What the trial is testing?

LY3002813, Placebo (IV),

Could I receive a Placebo?

yes

Enrollment Goal

266

Trial Dates

December 2017 - November 2021

Trial Phase

2

Not the right fit? Sign up to receive updates on new Early Symptoms of Alzheimer's Disease trials.

Trial Locations

Hide locations not currently recruiting

Enter your postal code to see sites near you

Early Symptoms of Alzheimer's Disease Resources

Memory, Alzheimer’s Disease, and Research Studies

Memory, Alzheimer’s Disease, and Research Studies

With the help of research study participants, we are learning about aging, memory, and potential new approaches to fighting Alzheimer’s disease.
Clinical Trial Participation: What to Expect

Clinical Trial Participation: What to Expect

A clinical trial is a scientific study in people that helps to determine if and how a drug or therapy works. These can also be called clinical studies, or clinical research. Clinical research helps us answer specific questions about an investigational drug , such as: Is it effective? Is it more effective than another established treatment? Is it safe and/or what are its side effects?